99 related articles for article (PubMed ID: 28903344)
61. Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma.
Qi Y; Hu Y; Yang H; Zhuang R; Hou Y; Tong H; Feng Y; Huang Y; Jiang Q; Ji Q; Gu Q; Zhang Z; Tang X; Lu W; Zhou Y
Oncotarget; 2017 Aug; 8(33):54320-54330. PubMed ID: 28903344
[TBL] [Abstract][Full Text] [Related]
62. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion.
Bode-Lesniewska B; Frigerio S; Exner U; Abdou MT; Moch H; Zimmermann DR
Genes Chromosomes Cancer; 2007 Nov; 46(11):961-71. PubMed ID: 17647282
[TBL] [Abstract][Full Text] [Related]
63. A Patient with Myxoid/Round Cell Liposarcoma (MRCL) Involving the Well-known Translocation t(12;22): A Case Report with the Cytogenomic Landscape of this Rearrangement.
Tirado CA; Su W; Chia V; Zaki M; Tang R; Eastwood K; Guardiola MT; Rao A
J Assoc Genet Technol; 2022; 48(2):68-75. PubMed ID: 35660675
[TBL] [Abstract][Full Text] [Related]
64. [Detection of FUS-CHOP fusion gene in paraffin-embedded tissues and its clinicopathologic significance for myxoid/round cell liposarcomas].
Xiang H; Wang J; Sun MH; Lu L; Shui RH; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):28-32. PubMed ID: 15796878
[TBL] [Abstract][Full Text] [Related]
65. Myxoid liposarcoma and the mammalian target of rapamycin pathway.
Sanfilippo R; Dei Tos AP; Casali PG
Curr Opin Oncol; 2013 Jul; 25(4):379-83. PubMed ID: 23673410
[TBL] [Abstract][Full Text] [Related]
66. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
de Graaff MA; Yu JS; Beird HC; Ingram DR; Nguyen T; Juehui Liu J; Bolshakov S; Szuhai K; Åman P; Torres KE; Lev D; Nielsen TO; Bovée JV; Lazar AJ; Somaiah N
Lab Invest; 2016 Aug; 96(8):885-94. PubMed ID: 27270875
[TBL] [Abstract][Full Text] [Related]
67. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.
Martin NE; Gerke T; Sinnott JA; Stack EC; Andrén O; Andersson SO; Johansson JE; Fiorentino M; Finn S; Fedele G; Stampfer M; Kantoff PW; Mucci LA; Loda M
Mol Cancer Res; 2015 Oct; 13(10):1431-40. PubMed ID: 26124442
[TBL] [Abstract][Full Text] [Related]
68. Liposarcoma miRNA signatures identified from genome-wide miRNA expression profiling.
Zhou Y; Zhang Y; Huang Y; Tan R; Liu T; Zhuang R; Zhu M; Han W; Hou Y; Liu J; Zhang L; Jiang Y; Tong H; Shao Y; Zhu J; Lu W
Future Oncol; 2014 Jun; 10(8):1373-86. PubMed ID: 25052748
[TBL] [Abstract][Full Text] [Related]
69. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma.
Guo S; Lopez-Marquez H; Fan KC; Choy E; Cote G; Harmon D; Nielsen GP; Yang C; Zhang C; Mankin H; Hornicek FJ; Borger DR; Duan Z
PLoS One; 2014; 9(4):e93996. PubMed ID: 24695632
[TBL] [Abstract][Full Text] [Related]
70. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
71. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation.
Rodriguez R; Tornin J; Suarez C; Astudillo A; Rubio R; Yauk C; Williams A; Rosu-Myles M; Funes JM; Boshoff C; Menendez P
Stem Cells; 2013 Oct; 31(10):2061-72. PubMed ID: 23836491
[TBL] [Abstract][Full Text] [Related]
72. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
[TBL] [Abstract][Full Text] [Related]
73. Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition.
Smith KB; Tran LM; Tam BM; Shurell EM; Li Y; Braas D; Tap WD; Christofk HR; Dry SM; Eilber FC; Wu H
Am J Pathol; 2013 Apr; 182(4):1400-11. PubMed ID: 23416162
[TBL] [Abstract][Full Text] [Related]
74. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy.
Wang WL; Katz D; Araujo DM; Ravi V; Ludwig JA; Trent JC; Patel SR; Lin PP; Guadagnolo A; Lòpez-Terrada D; Dei Tos AP; Lewis VO; Lev D; Pollock RE; Zagars GK; Benjamin RS; Madewell JE; Lazar AJ
Clin Sarcoma Res; 2012 Dec; 2(1):25. PubMed ID: 23272660
[TBL] [Abstract][Full Text] [Related]
75. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
[TBL] [Abstract][Full Text] [Related]
76. Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma.
Haniball J; Sumathi VP; Kindblom LG; Abudu A; Carter SR; Tillman RM; Jeys L; Spooner D; Peake D; Grimer RJ
Sarcoma; 2011; 2011():538085. PubMed ID: 22190864
[TBL] [Abstract][Full Text] [Related]
77. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Demicco EG; Torres KE; Ghadimi MP; Colombo C; Bolshakov S; Hoffman A; Peng T; Bovée JV; Wang WL; Lev D; Lazar AJ
Mod Pathol; 2012 Feb; 25(2):212-21. PubMed ID: 22020193
[TBL] [Abstract][Full Text] [Related]
78. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
79. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
